James Crowe Jr. Archives
VUMC team’s COVID-19 research featured on “60 Minutes”
Apr. 12, 2021—James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”
Crowe receives SEC Faculty Achievement Award
Apr. 12, 2021—James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
Novel way to neutralize Rift Valley Fever Virus
Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
Study shows new COVID target could improve vaccines
Apr. 1, 2021—Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
Monoclonal antibody “cocktail” blocks COVID-19 variants: study
Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
Chikungunya antibody identified at VUMC moves forward
Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Exploiting viral vulnerabilities
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research
Dec. 1, 2020—James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.
Study identifies antibodies that block alphaviruses
Aug. 20, 2020—Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.
Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
